Market Closed -
Nasdaq
03:59:47 2024-06-04 pm EDT
5-day change
1st Jan Change
0.96
USD
-0.35%
+2.12%
-30.43%
Presentation Operator MessageOperator (Operator)Good morning, ladies and gentlemen, thank you ...
Bluebird bio, Inc. Announces Executive Changes, Effective from June 10, 2024
May. 29
CI
Bluebird bio, Inc. Announces Chief Financial Officer Changes, Effective June 10, 2024
May. 29
CI
Transcript : Bluebird bio, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 10:00 AM
May. 16
Transcript : Bluebird bio, Inc., Q1 2024 Earnings Call, May 09, 2024
May. 09
Bluebird Bio, Inc. Announces Completion of First Cell Collection for LYFGENIA Gene Therapy
May. 06
CI
Bluebird Bio, Inc. Enters into an Amendment to Its Loan and Security Agreement
May. 03
CI
Bluebird bio Gets Nasdaq Notice for Late Filing of Annual Report
Apr. 26
MT
Wells Fargo Trims Price Target on Bluebird Bio to $3 From $4, Maintains Equalweight Rating
Mar. 27
MT
Wedbush Adjusts bluebird bio's PT to $1.72 From $1.68, Maintains Neutral Rating
Mar. 27
MT
Bluebird bio to Restate Financial Statements; Shares Fall
Mar. 26
MT
Wedbush Adjusts Bluebird Bio Price Target to $1.72 From $1.68, Maintains Neutral Rating
Mar. 26
MT
Transcript : Bluebird bio, Inc., Q4 2023 Earnings Call, Mar 26, 2024
Mar. 26
Gene therapy maker bluebird to restate 2022 financials after accounting error
Mar. 26
RE
Wedbush Adjusts bluebird bio's Price Target to $1.68 From $3, Maintains Neutral Rating
Mar. 19
MT
Sector Update: Health Care Stocks Edge Up Late Monday Afternoon
Mar. 18
MT
Sector Update: Health Care
Mar. 18
MT
Bluebird bio Secures $175 Million Term Loan Facility
Mar. 18
MT
Bluebird bio, Inc. Enters into $175 Million Five-Year, Term Loan Facility with Hercules Capital, Inc
Mar. 18
CI
Bluebird bio, Inc. announced that it expects to receive $175 million in funding
Mar. 17
CI
Bluebird bio, Inc.(NasdaqGS:BLUE) dropped from S&P Biotechnology Select Industry Index
Mar. 17
CI
Bluebird bio Signs Medicaid Agreement for Sickle Cell Disease Therapy with Michigan State
Mar. 11
MT
Bluebird bio, Inc. Announces First Outcomes-Based Agreement with Medicaid for Sickle Cell Disease Gene Therapy
Mar. 11
CI
HSBC Adjusts bluebird bio's Price Target to $1.02 From $2.31, Keeps Reduce Rating
Mar. 05
MT
Certain Pre-Funded Warrants of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.
Feb. 02
CI
Certain Units of bluebird bio, Inc. are subject to a Lock-Up Agreement Ending on 3-FEB-2024.
Feb. 02
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
bluebird bio, Inc. is a biotechnology company. The Company is focused on researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its lentiviral vector (LVV) gene addition platform. Its lead gene therapy programs for sickle cell disease, B-thalassemia, and cerebral adrenoleukodystrophy and is advancing research to apply new technologies to these and other diseases. It has two gene therapies: ZYNTEGLO (betibeglogene autotemcel) and SKYSONA (elivaldogene autotemcel). ZYNTEGLO is the first gene therapy for people with B-thalassemia who require regular red blood cell transfusions. SKYSONA (elivaldogene autotemcel), also known as eli-cel, is used to slow the progression of eurologic dysfunction in boys 4-17 years of age with early, active cerebral adrenoleukodystrophy (CALD). It is also developing (lovotibeglogene autotemcel), also known as lovo-cel, as a one-time treatment for patients with sickle cell disease (SCD).
More about the company
Last Close Price
0.9685
USD
Average target price
3.795
USD
Spread / Average Target
+291.80%
Consensus
1st Jan change
Capi.
-30.43% 186M +16.73% 121B +13.04% 107B -5.80% 24.82B +1.69% 22.48B -10.09% 18.32B -40.52% 16.33B -14.00% 15.31B +1.18% 14.08B +24.18% 11.74B
Bio Therapeutic Drugs
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1